Stocktoria
Spero Therapeutics, Inc. SPRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-11-02
Spero Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M |
| R&D expense | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Income tax | $261,000 | $0 | $2.6M | $0 | $0 |
| Net income | $8.6M | -$68.6M | $22.8M | — | -$89.8M |
| EPS (diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M |
| Cash & equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
| Shareholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M |
Source: SEC EDGAR filings · CIK 0001701108 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.